#Ireland #Dublin #LUMA Vision #VERAFEYE #cardiac procedures

LUMA Vision Secures FDA Clearance for VERAFEYE

LUMA Vision, a pioneering company in the med-tech space, has achieved a notable milestone with the recent FDA clearance for its advanced procedural intelligence platform, VERAFEYE. This innovative technology aims to enhance minimally invasive cardiac procedures by unifying imaging, visualization, navigation, and guidance into a comprehensive system. The FDA’s approval is a crucial step towards a more sophisticated approach to cardiac procedures, and the company is gearing up for a commercial launch planned for early 2027.

The Vision for the Future of Cardiac Labs

The goal of LUMA Vision is clear: to create the cardiac lab of the future. With the FDA's backing, VERAFEYE sets a new standard in procedural intelligence, offering physicians the ability to maintain continuous real-time visibility of the anatomy during procedures. This integrated platform not only provides exceptional imaging but also tracks mapping and guides therapies effortlessly, changing how cardiologists interact with and manage their patients' cardiac health.

The VERAFEYE platform leverages a unique 360° imaging catheter that captures raw ultrasound data to build real-time two-dimensional (2D) and three-dimensional (3D) representations of the patient's heart. This allows physicians to view an accurate anatomical map, enabling them to visualize critical structures such as heart valves, major vessels, and surrounding features, all in real time.

Combining Features for Seamless Procedures

At the core of VERAFEYE’s functionality is its ability to synchronize imaging, visualization, and catheter tracking seamlessly. Dr. Devi Nair, Chief of Cardiac Electrophysiology Research at St. Bernards Healthcare, emphasizes the revolutionary aspect of this technology: “What stands out about VERAFEYE is its ability to combine real-time imaging, visualization, and catheter tracking into a single integrated AI-driven platform.” This integration allows doctors to receive ongoing anatomical and procedural context without interruption, thereby enhancing focus on patient care.

Enhanced Navigation and Guidance

One of the standout features of VERAFEYE is its continuous tracking of both imaging and ablation catheters, ensuring uninterrupted visibility of the treatment area. This capability means that physicians no longer need to pause to reposition equipment, which can often lead to delays or complications during delicate procedures. Moreover, as ablation therapy is administered, clinicians can mark specific locations on the anatomical model, fostering alignment confirmation and boosting their confidence without sacrificing efficiency.

As a result of its advanced data collection and analysis, VERAFEYE will develop a comprehensive database of real anatomy that will aid healthcare professionals in future procedural decisions, transitioning the focus from mere visualization to actionable guidance.

Looking Ahead: A Paradigm Shift in Cardiac Care

Fionn Lahart, CEO and co-founder of LUMA Vision, describes this FDA clearance as “another step toward the cardiac lab of the future.” He highlights the significance of integrating multiple functionalities into one cohesive platform: “By combining imaging, visualization, navigation, and guidance, VERAFEYE delivers substantial clinical benefits with minimal disruption to existing workflows.” This evolution represents a paradigm shift in how arrhythmia procedures are guided and executed.

LUMA Vision remains committed to enhancing patient care and clinical outcomes through cutting-edge technologies like VERAFEYE. As they prepare for their upcoming commercial launch, more information can be found on their website: www.lumavision.com.

About LUMA Vision

Founded in Dublin, Ireland, LUMA Vision is dedicated to advancing healthcare through innovative medical technologies. They are focused on addressing global unmet clinical needs by developing groundbreaking products that significantly improve patient outcomes. With the VERAFEYE platform, they are poised to lead the way in cardiac visualization and navigational technology, aiming to enhance the quality of life for patients worldwide.